NY AG Takes Up Pay-For-Delay Mantle With Teva Deal

Law360, New York (February 19, 2014, 7:27 PM EST) -- Generic-drug makers Teva Pharmaceuticals USA Inc. and Ranbaxy Pharmaceuticals Inc. on Wednesday promised to put an end to an agreement that kept them from challenging each other's so-called first-filer exclusivity periods, as part of a settlement with New York's attorney general that shows the watchdog's desire to push the reach of pay-for-delay case law.

The pharmaceutical companies agreed to pay the state $300,000 and terminate the agreement, an unusual provision included in a broader deal covering the sale of generic Lipitor, New York Attorney General Eric...
To view the full article, register now.